The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...
Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
Number of Lawsuits Increases Fivefold to Over 2,100 Since May- FDA Approves Brain Tumour WarningGlobal pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection ...
The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...
Pfizer Inc. secures Metsera, Inc. acquisition, outbidding Novo Nordisk, with a deal valued up to $86.25 per share including milestone CVRs. The board favored PFE's offer due to higher certainty of ...
Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback